FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

肽库

FOX04-DRI

FOXO4-DRI / Proxofim

Fat Loss & Body Composition

FOXO4-DRI is a D-retro-inverso peptide designed to selectively induce apoptosis in senescent cells by disrupting the interaction between FOXO4 and p53 transcription factors that maintains senescent cell viability. Developed at Erasmus University Medical Center in the Netherlands, it was published in a landmark 2017 Cell paper demonstrating restoration of fitness, fur density, and renal function in naturally aged mice. The D-retro-inverso modification (all D-amino acids in reverse sequence) provides exceptional resistance to proteolytic degradation while maintaining the spatial orientation needed for protein-protein interaction disruption.

作用机制

D-retro-inverso peptide that disrupts the interaction between FOXO4 and p53 in senescent cells. Forces p53 into the mitochondria of senescent cells, triggering selective apoptosis (senolysis). Clears senescent cells without affecting healthy cells.

研究协议

仅供研究使用,非医疗建议。

Research protocols in mice used 5mg/kg IV every 3 days for 3 doses. Human protocols not established. Extremely expensive. Some anecdotal reports use 10-20mg subcutaneously over multi-day protocols.

研究笔记

Clinical Research Status

FOXO4-DRI was described in a 2017 publication in Cell by Baar et al. from Erasmus University Medical Center, representing a proof-of-concept for targeted senolytic therapy through protein-protein interaction disruption. No human clinical trials have been initiated, and the compound remains in the academic research phase with significant challenges remaining for clinical translation including manufacturing cost, delivery, dosing, and safety characterization. The concept has inspired pharmaceutical industry investment in senolytic therapies, though most clinical programs pursue small molecule approaches rather than peptide-based senolytics.

Key Published Findings

The original Cell paper demonstrated that FOXO4-DRI selectively induces apoptosis in senescent cells by competing with endogenous FOXO4 for p53 binding, releasing p53 from nuclear exclusion and enabling it to trigger mitochondrial apoptosis. In naturally aged mice, treatment restored fitness, fur density, and renal function while reducing senescence markers in multiple tissues. Irradiation-induced senescent cells and chemotherapy-damaged cells were also effectively cleared, suggesting broad applicability across different senescence triggers. The selectivity arises because only senescent cells depend on FOXO4-p53 interaction for survival.

Safety Profile

The original publication reported no apparent toxicity in treated mice at effective senolytic doses, with selective killing of senescent cells and sparing of proliferating and quiescent normal cells. The D-retro-inverso modification provides proteolytic stability but may also complicate clearance and raise concerns about accumulation with repeated dosing. Long-term safety data beyond the original publication's observation period is not available, and potential effects on stem cell populations that share some senescence markers remain a theoretical concern.

Comparison to Related Compounds

FOXO4-DRI differs from small molecule senolytics like dasatinib + quercetin (D+Q) and navitoclax by targeting a specific protein-protein interaction rather than broad anti-apoptotic pathways (BCL-2 family). The peptide approach offers potentially greater selectivity for senescent cells compared to navitoclax's dose-limiting thrombocytopenia, but faces greater challenges in drug delivery and manufacturing cost. Fisetin, another senolytic, operates through different mechanisms and has the advantage of oral bioavailability and established safety as a dietary compound, though with lower demonstrated senolytic potency.

Community Observations

FOXO4-DRI generated enormous excitement in the longevity community upon publication, with some individuals attempting self-experimentation despite the very early stage of research and extremely high synthesis cost. The D-retro-inverso peptide is technically challenging and expensive to manufacture at high purity, with costs reported at several thousand dollars per treatment course from custom synthesis services. Most longevity researchers recommend established senolytics like dasatinib + quercetin or fisetin for those interested in senolytic therapy, given their superior safety data, oral availability, and dramatically lower cost compared to FOXO4-DRI.

半衰期

~Unknown

复溶

DMSO or PBS

存储

冻干

Store at -20C. Protect from light.

复溶后

Store at -20C. Prepare fresh.

美国法律状态

Research chemical (not FDA-approved)

又称作

FOXO4-DRIProxofim

常见问题

什么是 FOX04-DRI?

FOXO4-DRI is a D-retro-inverso peptide designed to selectively induce apoptosis in senescent cells by disrupting the interaction between FOXO4 and p53 transcription factors that maintains senescent cell viability. Developed at Erasmus University Medical Center in the Netherlands, it was published in a landmark 2017 Cell paper demonstrating restoration of fitness, fur density, and renal function in naturally aged mice. The D-retro-inverso modification (all D-amino acids in reverse sequence) provides exceptional resistance to proteolytic degradation while maintaining the spatial orientation needed for protein-protein interaction disruption.

FOX04-DRI 如何起作用?

D-retro-inverso peptide that disrupts the interaction between FOXO4 and p53 in senescent cells. Forces p53 into the mitochondria of senescent cells, triggering selective apoptosis (senolysis). Clears senescent cells without affecting healthy cells.

FOX04-DRI 在美国的监管状态是什么?

Research chemical (not FDA-approved)

FOX04-DRI 的半衰期是多少?

~Unknown

FOX04-DRI 还有哪些名称?

FOXO4-DRI, Proxofim

Peptide Contacts仅提供基于研究的摘要,仅供信息参考。我们不托管、分发或支持供应商文档。所有证书分析、GMP证书和供应商通信必须由买家直接请求并验证。本平台上任何内容均不构成法律、医疗或专业建议。用户在购买任何研究化学品之前应自行核实供应商资质,并确保遵守所有适用的当地、州及联邦法律法规,承担全部法律责任。

阅读完整免责声明